MA71245A - Procédés de fabrication d'inhibiteurs de btk modifiés - Google Patents

Procédés de fabrication d'inhibiteurs de btk modifiés

Info

Publication number
MA71245A
MA71245A MA71245A MA71245A MA71245A MA 71245 A MA71245 A MA 71245A MA 71245 A MA71245 A MA 71245A MA 71245 A MA71245 A MA 71245A MA 71245 A MA71245 A MA 71245A
Authority
MA
Morocco
Prior art keywords
methods
btk inhibitors
manufacturing modified
modified btk
manufacturing
Prior art date
Application number
MA71245A
Other languages
English (en)
Inventor
Timothy D. Owens
Timothy J. Turner
JR John L. KANE
Original Assignee
Principia Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc. filed Critical Principia Biopharma Inc.
Publication of MA71245A publication Critical patent/MA71245A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA71245A 2022-06-22 2023-06-21 Procédés de fabrication d'inhibiteurs de btk modifiés MA71245A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263354330P 2022-06-22 2022-06-22
EP23741866.0A EP4543867A1 (fr) 2022-06-22 2023-06-21 Procédés de fabrication d'inhibiteurs de btk modifiés
PCT/US2023/025808 WO2023249980A1 (fr) 2022-06-22 2023-06-21 Procédés de fabrication d'inhibiteurs de btk modifiés

Publications (1)

Publication Number Publication Date
MA71245A true MA71245A (fr) 2025-04-30

Family

ID=87312140

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71245A MA71245A (fr) 2022-06-22 2023-06-21 Procédés de fabrication d'inhibiteurs de btk modifiés

Country Status (13)

Country Link
US (1) US20260022123A1 (fr)
EP (1) EP4543867A1 (fr)
JP (1) JP2025521510A (fr)
KR (1) KR20250025711A (fr)
CN (1) CN119343340A (fr)
AR (1) AR129672A1 (fr)
AU (1) AU2023287610A1 (fr)
CA (1) CA3259743A1 (fr)
IL (1) IL317768A (fr)
MA (1) MA71245A (fr)
MX (1) MX2024015814A (fr)
TW (1) TW202413364A (fr)
WO (1) WO2023249980A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006854A (es) 2020-12-10 2023-07-20 Genzyme Corp Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
CN121605107A (zh) * 2023-08-01 2026-03-03 普林斯匹亚生物制药公司 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8962831B2 (en) * 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
LT2718270T (lt) * 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
AU2013312296B2 (en) * 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EP4112618A1 (fr) * 2015-06-03 2023-01-04 Principia Biopharma Inc. Inhibiteurs de kinase de tyrosine
AU2021283916A1 (en) * 2020-06-02 2023-01-05 Vidya Therapeutics, Inc. Kinase inhibitors
WO2022140511A1 (fr) * 2020-12-23 2022-06-30 Genzyme Corporation Dérivés de 4-amino-3-(4-phénoxyphényl)-1,3-dihydro-2 h-imidazo[4,5-c]pyridin-2-one et leurs sels

Also Published As

Publication number Publication date
MX2024015814A (es) 2025-02-10
CN119343340A (zh) 2025-01-21
AU2023287610A1 (en) 2025-02-06
CA3259743A1 (fr) 2023-12-28
JP2025521510A (ja) 2025-07-10
US20260022123A1 (en) 2026-01-22
EP4543867A1 (fr) 2025-04-30
TW202413364A (zh) 2024-04-01
KR20250025711A (ko) 2025-02-24
IL317768A (en) 2025-02-01
WO2023249980A1 (fr) 2023-12-28
AR129672A1 (es) 2024-09-18

Similar Documents

Publication Publication Date Title
MA71245A (fr) Procédés de fabrication d'inhibiteurs de btk modifiés
EP4013853A4 (fr) Procédés améliorés de fabrication de compositions organoïdes
EP3797015A4 (fr) Tampons de polissage formés par un procédé de fabrication additive et procédés associés
EP4272246A4 (fr) Porte-substrat électrostatique produit par fabrication additive et procédés et structures associés
EP4175425A4 (fr) Plaque de cuivre plaquée de céramique et procédé de fabrication de plaque de cuivre plaquée de céramique
EP3817119A4 (fr) Composition d'électrolyte, film d'électrolyte et procédé de fabrication de film d'électrolyte
MA46204A (fr) Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication
EP4164653A4 (fr) Formes morphiques de trilaciclib et leurs procédés de fabrication
LT4157831T (lt) Jak1 inhibitoriaus gamybos būdas
EP4254539A4 (fr) Électrode et procédé de fabrication d'électrode
EP4012080A4 (fr) Procédé de fabrication d'un substrat en sic
EP4467529A4 (fr) Procédé d'isolement
EP4163955A4 (fr) Procédé de fabrication d'élément semi-conducteur sic et élément semi-conducteur sic
EP4075516A4 (fr) Procédé de fabrication de substrat semi-conducteur et substrat semi-conducteur
EP4447093A4 (fr) Procédé de fabrication de tranche
EP1801854A4 (fr) Procédé de fabrication de plaquette semi-conductrice
EP4294145A4 (fr) Structure semi-conductrice et procédé de fabrication de structure semi-conductrice
EP3750173A4 (fr) Procédés de fabrication d'un supraconducteur
EP1811543A4 (fr) Procédé de fabrication de plaquette semi-conductrice
EP3940374A4 (fr) Procédé d'inspection de produit façonné, et procédé de fabrication de produit façonné
EP4535398A4 (fr) Dispositif de traitement de semi-conducteurs
EP4007462A4 (fr) Procédé de fabrication de composants d'empilement
EP4293768A4 (fr) Procédé de fabrication d'ensemble électrode
EP4143157A4 (fr) Procédés de fabrication de dianhydrides
EP4166869A4 (fr) Plaque de réfrigération à semi-conducteurs et procédé de fabrication associé